Chapter

TRITON: Tremelimumab Plus Durvalumab and Chemotherapy

From ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor by Bryant Furlow

Concepts

1. TRITON Findings

   "Among patients with nonsquamous metastatic NSCLC harboring STK11, KEAP1, or KRAS mutations that tend to respond poorly to standard immune checkpoint inhibition, adding the CTLA-4 inhibitor tremelimum

2. Trial Results

   "In this phase 2b trial (NCT06008093), researchers randomly assigned 84 patients to receive T+D+CT (n=41) or P+CT (n=43). According to the presentation abstract, patients in the first group received 7

3. Safety Outlook

   "The incidence of adverse events was similar between the treatment arms, with low rates of discontinuation and no new safety signals, he said. The incidence of adverse events was similar between the 2